At a glance
ClinicalIndex Comparison RecordPhase 1Unknown· 30 target
Drug / intervention
HS-10241drug
Likely dose
HS-10241 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Single and Multiple Doses of Oral Administration of HS-10241 in Patients With Locally Advanced or Metastatic Solid Tumors Who Have Progressed Following Prior Therapy
In Brief
A Phase 1 clinical trial evaluating HS-10241 for Solid Tumor. Targeting 30 participants across 1 site.
Detailed Summary
HS-10241 is a highly potent and selective small molecule inhibitor of c-Met kinase. In preclinical studies, it demonstrated strong activity against c-Met kinase in vitro and in vivo, and inhibited tumor cell growth. This study is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-10241 at single dose and multiple doses.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesChina
Collaborators--
Timeline
Phase 1UnknownOverdue
2020202120222023202420252026
Enrollment StartJun 2019
First PostedJul 2020
Primary CompletionDec 2020
Study CompletionDec 2021
TodayJul 2026
First PostedJul 20, 2020
Enrollment StartJun 21, 2019
Primary CompletionDec 31, 2020
Study CompletionDec 31, 2021
TodayJul 1, 2026
Enrollment to primary: 1.5 yearsPosted 5.9 years ago
Interventions
HS-10241drug
HS-10241 is a tablet in the form of 100 mg, oral, once daily.